Treatment therapies for adults with RSV have been elusive, but there are promising breakthroughs on the horizon. Join Drs Forest Arnold and Richard Plemper as they discuss.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/985980). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cell Entry of Enveloped Viruses https://pubmed.ncbi.nlm.nih.gov/21927634/

Product Review on the Monoclonal Antibody Palivizumab for Prevention of Respiratory Syncytial Virus Infection https://pubmed.ncbi.nlm.nih.gov/28605249/

Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Children https://pubmed.ncbi.nlm.nih.gov/34783356/

Nirsevimab: A Promising Therapy for RSV https://pubmed.ncbi.nlm.nih.gov/35544094/

Nirsevimab for Prevention of RSV in Healthy Late-preterm and Term Infants https://pubmed.ncbi.nlm.nih.gov/35235726/

Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study https://pubmed.ncbi.nlm.nih.gov/25140957/

A Phase 2b, Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Lower Respiratory Tract https://pubmed.ncbi.nlm.nih.gov/31915807/

Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-infected Hospitalized Infants at 12th International RSV Symposium https://www.globenewswire.com/en/news-release/2022/10/07/2530040/0/en/Ark-Biopharmaceutical-Presents-Positive-Results-in-Phase-3-AIRFLO-Study-of-Ziresovir-in-RSV-Infected-Hospitalized-Infants-at-12th-International-RSV-Symposium.html

Structural Insight Into Paramyxovirus and Pneumovirus Entry Inhibition https://pubmed.ncbi.nlm.nih.gov/32245118/

Molnupiravir for Treatment of COVID-19 https://pubmed.ncbi.nlm.nih.gov/35134041/

NIH COVID-19 Treatment Guidelines—Molnupiravir https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/

Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model https://pubmed.ncbi.nlm.nih.gov/31945316/

Compound Summary Molnupiravir https://pubchem.ncbi.nlm.nih.gov/compound/Molnupiravir